Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Insulatard til behandling af sukkersyge er større end risiciene.
The Committee for Medicinal products for Human Use (CHMP) decided that Insulatard’ s benefits are greater than its risks for the treatment of diabetes.